# DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

> **NCT02555943** · PHASE2,PHASE3 · COMPLETED · sponsor: **Humanity and Health Research Centre** · enrollment: 23 (actual)

## Conditions studied

- Chronic Hepatitis C Infection
- HBV Coinfection
- Hepatitis B Reactivation

## Interventions

- **DRUG:** Ledipasvir/Sofosbuvir
- **DRUG:** Sofosbuvir and Daclatasvir
- **DRUG:** Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
- **DRUG:** Entecavir
- **DRUG:** Tenofovir disoproxil

## Key facts

- **NCT ID:** NCT02555943
- **Lead sponsor:** Humanity and Health Research Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2021-05
- **Final completion:** 2021-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-09-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555943, "DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02555943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*